Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

OBJECTIVE: We reported previously that empagliflozin—a sodium-glucose cotransporter (SGLT) 2 inhibitor—exhibited preventive effects against obesity. However, it was difficult to extrapolate these results to human subjects. Here, we performed a therapeutic study, which is more relevant to clinical si...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open Diabetes Res Care
Autors principals: Xu, Liang, Nagata, Naoto, Chen, Guanliang, Nagashimada, Mayumi, Zhuge, Fen, Ni, Yinhua, Sakai, Yuriko, Kaneko, Shuichi, Ota, Tsuguhito
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Obesity Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827766/
https://ncbi.nlm.nih.gov/pubmed/31749970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2019-000783
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars